<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517488</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb20717-01</org_study_id>
    <secondary_id>DUET-2</secondary_id>
    <nct_id>NCT03517488</nct_id>
  </id_info>
  <brief_title>A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors</brief_title>
  <acronym>DUET-2</acronym>
  <official_title>A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and&#xD;
      regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity,&#xD;
      and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability profile of XmAb20717</measure>
    <time_frame>56 Days</time_frame>
    <description>Treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Melanoma</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <condition>Gastric or Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <condition>Mesothelioma</condition>
  <condition>Neuroendocrine Carcinoma</condition>
  <condition>Cervical Cancer</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Anus</condition>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Thymoma</condition>
  <condition>Thymic Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Penis</condition>
  <condition>Vulvar Carcinoma</condition>
  <condition>Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy</condition>
  <condition>Malignant Adnexal Neoplasms</condition>
  <condition>Non-squamous Cell Salivary Gland Carcinoma</condition>
  <arm_group>
    <arm_group_label>XmAb20717</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb20717</intervention_name>
    <description>Monoclonal bispecific antibody</description>
    <arm_group_label>XmAb20717</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of one of the following advanced&#xD;
             solid tumors:&#xD;
&#xD;
        PART A (Dose Escalation Cohorts)&#xD;
&#xD;
          1. Melanoma;&#xD;
&#xD;
          2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative&#xD;
             (triple-negative breast cancer; TNBC);&#xD;
&#xD;
          3. Hepatocellular carcinoma;&#xD;
&#xD;
          4. Urothelial carcinoma;&#xD;
&#xD;
          5. Squamous cell carcinoma of the head and neck;&#xD;
&#xD;
          6. Renal cell carcinoma (clear cell predominant type);&#xD;
&#xD;
          7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or&#xD;
             endometrial carcinoma;&#xD;
&#xD;
          8. Non-small cell lung carcinoma;&#xD;
&#xD;
          9. Gastric or gastroesophageal junction adenocarcinoma&#xD;
&#xD;
         10. Mesothelioma;&#xD;
&#xD;
         11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung&#xD;
&#xD;
         12. Cervical cancer;&#xD;
&#xD;
         13. Squamous cell carcinoma of the anus&#xD;
&#xD;
        PART B (Dose Expansion Cohorts):&#xD;
&#xD;
          1. Melanoma&#xD;
&#xD;
          2. Renal cell carcinoma (clear cell predominant type)&#xD;
&#xD;
          3. Non-small cell lung carcinoma&#xD;
&#xD;
          4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease&#xD;
             after surgical castration, or progression in the setting of medical androgen ablation&#xD;
             with a castrate level of testosterone (&lt; 50 ng/dL)&#xD;
&#xD;
          5. Nasopharyngeal carcinoma&#xD;
&#xD;
          6. Cholangiocarcinoma&#xD;
&#xD;
          7. Basal cell carcinoma&#xD;
&#xD;
          8. Squamous cell carcinoma of the anus&#xD;
&#xD;
          9. Mesothelioma&#xD;
&#xD;
         10. Ovarian or fallopian tube carcinoma&#xD;
&#xD;
         11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma,&#xD;
             trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma,&#xD;
             adnexal carcinoma with divergent differentiation, papillary digital eccrine&#xD;
             adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)&#xD;
&#xD;
         12. Thymoma&#xD;
&#xD;
         13. Thymic carcinoma&#xD;
&#xD;
         14. Squamous cell carcinoma of the penis&#xD;
&#xD;
         15. Neuroendocrine carcinoma&#xD;
&#xD;
         16. Vulvar cancer&#xD;
&#xD;
         17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma)&#xD;
&#xD;
         18. Subjects with other solid tumors for which there is published evidence of anti-tumor&#xD;
             activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is&#xD;
             no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be&#xD;
             eligible for Part B after approval by the Medical Monitor.&#xD;
&#xD;
               -  All subjects' cancer must have progressed after treatment with all standard&#xD;
                  therapies or have no appropriate available therapies.&#xD;
&#xD;
               -  Subjects, except those with adenocarcinoma of the prostate, must have measurable&#xD;
                  disease by RECIST 1.1.&#xD;
&#xD;
               -  Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides&#xD;
                  containing tumor or adequate pre-dose fresh tumor biopsy tissue&#xD;
&#xD;
               -  ECOG performance status of 0 - 1&#xD;
&#xD;
               -  Subjects with adenocarcinoma of the prostate must have evaluable disease&#xD;
                  (measurable or nonmeasurable lesions) by PCWG3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects currently receiving other anticancer therapies, with the exception of&#xD;
             subjects with adenocarcinoma of the prostate, who may continue luteinizing&#xD;
             hormone-releasing hormone (LHRH) analogue therapy.&#xD;
&#xD;
          -  Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.&#xD;
&#xD;
          -  Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the&#xD;
             start of study drug.&#xD;
&#xD;
          -  Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort&#xD;
             dependent).&#xD;
&#xD;
          -  Treatment with any other anticancer therapy within 2 weeks of the start of study drug&#xD;
             (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with&#xD;
             prostate cancer may continue LHRH analogue therapy.&#xD;
&#xD;
          -  A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy.&#xD;
&#xD;
          -  Failure to recover from any immune-related toxicity from prior cancer therapy to ≤&#xD;
             Grade 1, except if previous immune-related endocrinopathy is medically managed with&#xD;
             hormone replacement therapy only.&#xD;
&#xD;
          -  Failure to recover from any other toxicity (other than immune-related toxicity)&#xD;
             related to previous anticancer treatment to ≤ Grade 2.&#xD;
&#xD;
          -  Have known active CNS metastases and/or carcinomatous meningitis. Participants with&#xD;
             previously treated brain metastases may participate provided they are radiologically&#xD;
             stable, ie, are without evidence of progression for at least 4 weeks by repeat&#xD;
             imaging, are clinically stable, and without requirement of steroid treatment for at&#xD;
             least 14 days prior to first dose of study treatment.&#xD;
&#xD;
          -  Active known or suspected autoimmune disease (except that subjects are permitted to&#xD;
             enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due&#xD;
             to an autoimmune condition that is treatable with hormone replacement therapy only;&#xD;
             psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed&#xD;
             without systemic therapy; or arthritis that is managed without systemic therapy beyond&#xD;
             oral acetaminophen and non-steroidal anti-inflammatory drugs).&#xD;
&#xD;
          -  Has any condition requiring systemic treatment with corticosteroids, prednisone&#xD;
             equivalents, or other immunosuppressive medications within 14 days prior to first dose&#xD;
             of study drug (except that inhaled or topical corticosteroids or brief courses of&#xD;
             corticosteroids given for prophylaxis of contrast dye allergic response are&#xD;
             permitted).&#xD;
&#xD;
          -  Receipt of an organ allograft.&#xD;
&#xD;
          -  Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1&#xD;
             and CTLA-4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Hickingbottom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Xencor, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Hickingbottom, MD</last_name>
    <phone>858-480-3413</phone>
    <email>bhickingbottom@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Ely</last_name>
    <phone>858-480-3125</phone>
    <email>jely@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology Clinic (Westwood)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emily Couric Clinical Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DUET-2</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Hepatocellular Cancer</keyword>
  <keyword>Urothelial Cancer</keyword>
  <keyword>Renal Cell Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>MSI-high Colorectal Cancer</keyword>
  <keyword>MSI-high Endometrial Cancer</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastroesophageal Junction Cancer</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>High-grade Neuroendocrine Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>Anal Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Nasopharyngeal Cancer</keyword>
  <keyword>Bile Duct Cancer</keyword>
  <keyword>Basal Cell Skin Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <keyword>Malignant Adnexal Tumor</keyword>
  <keyword>Thymus Cancer</keyword>
  <keyword>Penile Cancer</keyword>
  <keyword>Vulvar Cancer</keyword>
  <keyword>Salivary Gland Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

